Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted

▤ Summary

Vcare PharmaTech’s Sumecigrel Capsule has had its NDA officially accepted by China’s NMPA, moving the drug into the review stage. The company positions Sumecigrel as a next-generation antiplatelet therapy aimed at improving the balance between efficacy and bleeding risk for cardiovascular and cerebrovascular patients. Vcare PharmaTech says it has completed key clinical studies and is preparing filings in the US, EU, and other markets. The company also has an exclusive regional licensing deal with Everest Medicines for the Asia-Pacific market, which supports its broader commercialization strategy.

▦ Linked Companies